Latest news with #KraigLabs
Yahoo
3 days ago
- Business
- Yahoo
Kraig Biocraft Laboratories Issues a Letter to Shareholders on Recent Advancements and Potential Recombinant Spider Silk Deliveries in 2025
ANN ARBOR, Mich., June 03, 2025 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) ("Company" or "Kraig Labs"), a world leader in spider silk technology*, issues a letter to Shareholders, We recently received inquiries from several of our shareholders. In preparing those responses, we realized that we should share the contents with the broader Kraig Labs community. Many had questions related to last week's announcement of the development of the new production strain and the potential for commercial deliveries in 2025. The development of a new spider silk production transgenic has been a key part of our production roadmap since 2023 and a primary objective of our genetics team during the last 18 months. Our longstanding plans were to field a new strain of silkworm for our double hybrid production system in the Summer of 2025. To be frank, we were unsure whether we could meet that ambitious schedule. We were, therefore, ecstatic to announce that we created another world's first development on schedule. This and many of our other laboratory announcements are not only significant; they're foundational technology building blocks to our success. Our current single hybrid system, utilizing BAM-1, has already shown massive improvement in robustness and silk production output. The newly announced strain is another significant improvement in our production, moving us a significant step closer to a more powerful double hybrid. The double hybrid model is designed to significantly improve our silk production rate; we expect by as much as 25+% per month, so this is something that we were very excited to share with our shareholders. We are no longer experiencing the robustness challenges we faced with single-strain rearing. Before the rollout of the BAM-1 hybrid in 2024, our silkworms lacked the robustness to deal with the silkworm diseases and environmental stress that are frequently present in the field. In terms of robustness and disease tolerance, the BAM-1 appears to be on par with the Chinese commercial silk hybrid, which is the gold standard in that region for the production of mundane silk. Now, this doesn't mean that we are invincible. Globally, between 10% to 30% of all silk production with robust double hybrids is lost due to a handful of diseases and adverse weather conditions. This is just a part of working with these living production systems. It is a fact that is reflected in global silk economics. Since rolling out the BAM-1, we have dealt with these routine challenges and have weathered these events with similar or identical effects as mundane silk producers utilizing the Chinese hybrid. Right now, the region's sericulture operators are in their rainy season, which is typically the worst time for silkworm rearing. Production of our BAM-1 strains and production of mundane silk producers utilizing Chinese hybrids are negatively impacted during this cycle. That is a normal part of silkworm rearing and is something that all silkworm producers encounter as a normal part of the business. In the past, before we introduced BAM-1, the effects on our silkworms were significantly magnified and effectively stymied our growth. In short, there has been a revolution in our spider silk production technology over the past 14 months due to the introduction of BAM-1 and other improvements in the field and laboratory. As we meet our marks toward the initiation of the double hybrid, we anticipate our gains to accelerate further. Regarding inventory calculation, our current inventory figures track finished raw reeled silk. In the first quarter of this year, we stockpiled several hundred kilograms of cocoon that are now waiting to be processed into finished silk. The reason inventory did not increase in our financial report was because that report tracked finished silk or material form. After considering these questions, and in light of the fact that we are moving from nominal inventory to larger scale production, we will expand the scope of our work-in-progress (WIP) material inventory to include recombinant spider silk cocoon that has been completed but not reeled. You can expect us to begin adding completed recombinant spider silk cocoon to our WIP to all future inventory balances. We are 100% focused on the production of spider silk for commercial delivery. Over the last year, we've been able to move faster to deliver on that commitment. As a great example, we are in regular communication with three major Global brands that are standing by to receive their first shipments of materials. The first is an internationally renowned high-end luxury fashion brand that has already accepted a quote from Kraig Labs. The second is a world leader in high-end performance sportswear with an approved budget to buy silk from us. The third is one of the world's top 5 performance athletic equipment producers, looking for spider silk to integrate into their top-performing products. Supplying products to these three entities is the focus of our current production. Currently, we expect to begin deliveries to these customers in the second half of this year. That will be a significant milestone for Kraig Labs, our shareholders, and material science. I believe the future for Kraig Labs and spider silk has never been brighter, and we thank you for your continued support. Kim Thompson, CEO For the latest updates on Kraig Labs and its pioneering spider silk technologies, visit For details about other recent Kraig Labs advancements, please watch the Company's investor conference at or on the Company's YouTube Channel To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to * For a description of our historical leadership in this technology, please follow this link About Kraig Biocraft Laboratories, Inc. Kraig Biocraft Laboratories, Inc. ( a reporting biotechnology company is the leading developer of genetically engineered spider silk-based fiber technologies. The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry. Cautionary Statement Regarding Forward Looking Information Statements in this press release about the Company's future and expectations other than historical facts are "forward-looking statements." These statements are made on the basis of management's current views and assumptions. As a result, there can be no assurance that management's expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as "believes," "plans," "expects," "anticipates," "foresees," "estimated," "hopes," "if," "develops," "researching," "research," "pilot," "potential," "could" or other words or phrases of similar import. Forward looking statements include descriptions of the Company's business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security. Ben Hansel, Hansel Capital, Inc.(720) 288-8495ir@ A photo accompanying this announcement is available at
Associated Press
28-05-2025
- Business
- Associated Press
Kraig Biocraft Laboratories Announces New Spider Silk Parental Strain for Expanded Commercial Production
ANN ARBOR, Mich., May 28, 2025 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) ('Company' or 'Kraig Labs'), a world leader in spider silk technology*, announces today the successful development of a new recombinant spider silk parental line, purpose-built for large-scale commercial production. This newly developed strain represents the third commercial production line created by Kraig Labs as it executes on its strategy to expand output capacity. The addition of this next-generation silk-producing line comes as the Company ramps up production to fulfill current material requests and strategically build inventory for future sales. 'Our team continues to deliver on key milestones as we scale the commercialization of spider silk,' said Company Founder and CEO, Kim Thompson. 'With the development of this new production strain, we are not only increasing our ability to meet existing demand, but also reinforcing the foundation for our future growth. This new strain is part of the production roadmap we outlined in 2024 and a key part of our transition to a full double hybrid production system.' This latest strain is part of Kraig Labs' broader development pipeline, which includes several additional parental lines currently in advanced stages of development. These lines are designed to enable a transition to a double hybrid production model—expected to deliver significant performance improvements, including higher silk yields, increased colony resilience, and reduced overall production costs. 'As we prepare to implement double hybrid crosses into our production platform, we are opening the door to greater scalability, efficiency, and product consistency,' Thompson continued. 'This is a key step forward in our mission to bring the power of spider silk to mainstream markets.' The Company is continuing its focus on building a robust and scalable production system as it transitions from pilot operations to full-scale manufacturing. For the latest updates on Kraig Labs and its pioneering spider silk technologies, visit . For details about other recent Kraig Labs advancements, please watch the Company's investor conference at or on the Company's YouTube Channel . To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to * For a description of our historical leadership in this technology, please follow this link About Kraig Biocraft Laboratories, Inc. Kraig Biocraft Laboratories, Inc. ( ), a reporting biotechnology company is the leading developer of genetically engineered spider silk-based fiber technologies. The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry. Cautionary Statement Regarding Forward Looking Information Statements in this press release about the Company's future and expectations other than historical facts are 'forward-looking statements.' These statements are made on the basis of management's current views and assumptions. As a result, there can be no assurance that management's expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as 'believes,' 'plans,' 'expects,' 'anticipates,' 'foresees,' 'estimated,' 'hopes,' 'if,' 'develops,' 'researching,' 'research,' 'pilot,' 'potential,' 'could' or other words or phrases of similar import. Forward-looking statements include descriptions of the Company's business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security. Ben Hansel, Hansel Capital, Inc. (720) 288-8495 [email protected]
Yahoo
28-05-2025
- Business
- Yahoo
Kraig Biocraft Laboratories Announces New Spider Silk Parental Strain for Expanded Commercial Production
Company Expands Capacity to Meet Material Demand and Scale Inventory by developing new parental Strain for Production ANN ARBOR, Mich., May 28, 2025 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) ("Company" or "Kraig Labs"), a world leader in spider silk technology*, announces today the successful development of a new recombinant spider silk parental line, purpose-built for large-scale commercial production. This newly developed strain represents the third commercial production line created by Kraig Labs as it executes on its strategy to expand output capacity. The addition of this next-generation silk-producing line comes as the Company ramps up production to fulfill current material requests and strategically build inventory for future sales. "Our team continues to deliver on key milestones as we scale the commercialization of spider silk," said Company Founder and CEO, Kim Thompson. "With the development of this new production strain, we are not only increasing our ability to meet existing demand, but also reinforcing the foundation for our future growth. This new strain is part of the production roadmap we outlined in 2024 and a key part of our transition to a full double hybrid production system." This latest strain is part of Kraig Labs' broader development pipeline, which includes several additional parental lines currently in advanced stages of development. These lines are designed to enable a transition to a double hybrid production model—expected to deliver significant performance improvements, including higher silk yields, increased colony resilience, and reduced overall production costs. "As we prepare to implement double hybrid crosses into our production platform, we are opening the door to greater scalability, efficiency, and product consistency," Thompson continued. "This is a key step forward in our mission to bring the power of spider silk to mainstream markets." The Company is continuing its focus on building a robust and scalable production system as it transitions from pilot operations to full-scale manufacturing. For the latest updates on Kraig Labs and its pioneering spider silk technologies, visit For details about other recent Kraig Labs advancements, please watch the Company's investor conference at or on the Company's YouTube Channel To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to * For a description of our historical leadership in this technology, please follow this link About Kraig Biocraft Laboratories, Inc. Kraig Biocraft Laboratories, Inc. ( a reporting biotechnology company is the leading developer of genetically engineered spider silk-based fiber technologies. The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry. Cautionary Statement Regarding Forward Looking Information Statements in this press release about the Company's future and expectations other than historical facts are "forward-looking statements." These statements are made on the basis of management's current views and assumptions. As a result, there can be no assurance that management's expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as "believes," "plans," "expects," "anticipates," "foresees," "estimated," "hopes," "if," "develops," "researching," "research," "pilot," "potential," "could" or other words or phrases of similar import. Forward-looking statements include descriptions of the Company's business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security. Ben Hansel, Hansel Capital, Inc.(720) 288-8495ir@ in to access your portfolio
Yahoo
15-05-2025
- Business
- Yahoo
Kraig Biocraft Laboratories Receives Business License to Begin Operations in Cambodia
New Location to Support Unprecedented 2025 Spider Silk Production Expansion ANN ARBOR, Mich., May 15, 2025 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) ('Company' or 'Kraig Labs'), a world leader in spider silk technology*, announces today that it has officially received its business license to begin operations in the Kingdom of Cambodia. This milestone marks a significant step in the Company's ongoing strategy to scale up and diversify its production capabilities in response to the exceptional success of its 2025 expansion initiatives. The Company's decision to launch operations in Cambodia is grounded in the continued positive momentum Kraig Labs has achieved through its expanded production efforts this year. 'This license represents more than just geographic growth—it's a reflection of the strong foundation we've built through our 2025 production expansion,' said Jon Rice, COO of Kraig Labs. 'Cambodia offers the right combination of climate, infrastructure, and opportunity to support the next phase of our spider silk production scale up. We are confident that this new location will play a role in helping continue to grow and diversity our production based for our spider silk materials.' The Cambodian business license is expected to support the Company's goals of increasing production capacity, while simultaneously diversifying its production footprint. As Kraig Labs embarks on this next phase of its business plan, it continues to invest in both research and infrastructure to advance the performance and scalability of its proprietary recombinant spider silk technologies. Kraig Labs remains committed to strengthening its production pipeline and establishing a global footprint that supports the commercial roll-out of next-generation biomaterials. For the latest updates on Kraig Labs and its pioneering spider silk technologies, visit For details about other recent Kraig Labs advancements, please watch the Company's investor conference at or on the Company's YouTube Channel To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to * For a description of our historical leadership in this technology, please follow this link About Kraig Biocraft Laboratories, Inc. Kraig Biocraft Laboratories, Inc. ( a reporting biotechnology company is the leading developer of genetically engineered spider silk-based fiber technologies. The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry. Cautionary Statement Regarding Forward Looking Information Statements in this press release about the Company's future and expectations other than historical facts are "forward-looking statements." These statements are made on the basis of management's current views and assumptions. As a result, there can be no assurance that management's expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as "believes," "plans," "expects," "anticipates," "foresees," "estimated," "hopes," "if," "develops," "researching," "research," "pilot," "potential," "could" or other words or phrases of similar import. Forward looking statements include descriptions of the Company's business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security. Ben Hansel, Hansel Capital, LLC(720) 288-8495ir@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
06-05-2025
- Business
- Yahoo
Kraig Biocraft Laboratories Successfully Completes March
Kraig Biocraft Laboratories Company Continues to Meet 2025 Scale-Up Targets ANN ARBOR, Mich., May 06, 2025 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) ("the Company" or "Kraig Labs"), a world leader in spider silk technology*, announces that it has successfully completed its March/April spider silk production run and is currently well underway with its May production cycle. Kraig Labs Recombinant Spider Silk Cocoons This steady progress reflects the Company's continued execution against its 2025 production scale-up plan, which builds on the significant operational and technical advancements achieved throughout 2024. Spider silk production for March and April met internal performance benchmarks and production targets, reinforcing confidence in the expanded capacity and workflow improvements implemented earlier this year. With May's production already in progress, Kraig Labs is maintaining its momentum and remains on track to meet its full-year production capacity goals. These efforts support Kraig Labs' broader strategy to transition recombinant spider silk from pilot-scale production to commercial viability across multiple markets. "Our teams in Vietnam and the U.S. continue to demonstrate consistent execution and focus," said Company Founder and CEO, Kim Thompson. "With each completed cycle, we are strengthening our manufacturing capabilities and moving closer to our goal of delivering commercial volumes of eco-friendly, performance fiber." The Company will provide further updates as it progresses through its 2025 production calendar. For the latest updates on Kraig Labs and its pioneering spider silk technologies, visit For details about other recent Kraig Labs advancements, please watch the Company's investor conference at or on the Company's YouTube Channel To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to * For a description of our historical leadership in this technology, please follow this link About Kraig Biocraft Laboratories, Inc. Kraig Biocraft Laboratories, Inc. ( ), a reporting biotechnology company is the leading developer of genetically engineered spider silk-based fiber technologies. The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry. Cautionary Statement Regarding Forward Looking Information
